BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Drug Development

  CSL Heart Attack Hopeful Fails to Meet Primary Endpoint in Phase III Trial

  CSL’s investigational cholesterol efflux enhancer CSL112 failed to reduce major adverse cardiovascular events within 90 days in patients who had just suffered a heart attack.

  February 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  Novo Claims First Victories in Legal Fight Against Compounded Semaglutide

  Two Florida courts have sided with Novo Nordisk against Ekzotika and Effinger Health, agreeing that their compounded versions of semaglutide are against the law. The Danish pharma has reached confidential settlements with both companies.

  February 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Bayer, Moderna-Backed Metagenomi’s Stock Crashes 31% in Friday IPO Debut

  Shares of preclinical genetic medicines company Metagenomi tanked more than 30% on Friday afternoon in a disappointing debut for its initial public offering, bucking the trend of positive IPOs so far this year.

  February 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  FDA Approves First One-Time Cell Therapy for a Solid Tumor

  On Friday, the regulator greenlit Iovance’s lifileucel to treat advanced melanoma. Prior to the approval, experts told BioSpace that tumor-infiltrating lymphocytes therapies also hold the potential to treat several other solid tumors.

  February 12, 2024

   · 

  6 min read

   · 

  Aayushi Pratap and Heather McKenzie
• 

  Business

  Medicxi Combines Six Portfolio Companies with $100M to Launch Alys Pharma

  Merging six of its portfolio biotechs, Medicxi on Monday unveiled Alys Pharmaceuticals, an immuno-dermatology focused company seeking to deliver up to 10 proof-of-concept readouts by the end of 2026.

  February 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Gilead to Buy CymaBay, Lead Liver Disease Asset Seladelpar for $4.3B

  Gilead Sciences announced Monday it will purchase CymaBay Therapeutics and its investigational treatment seladelpar for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.

  February 12, 2024

   · 

  3 min read

   · 

  Tyler Patchen
• Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS

  Poolbeg Pharma announces that independent research conducted on behalf of Poolbeg confirms a >$10 billion market opportunity for POLB 001 in Cancer Immunotherapy-Induced CRS as an orally delivered preventative therapy.

  February 12, 2024

   · 

  7 min read
• Orexo and Sobi agree to advance feasibility study with AmorphOX

  Orexo AB, announces the company agreed with Swedish Orphan Biovitrum AB to advance the successful exploratory feasibility study initiated last year.

  February 12, 2024

   · 

  3 min read
• Drug Development

  AlzeCure Pharma Broadcasts Live Expert Event on Alzheimer’s Around Highly Current Gamma-Secretase Modulators

  AlzeCure Pharma AB announced that the company will hold a live expert event on February 19 at 15:00 with Professor Henrik Zetterberg as special expert guest speaker.

  February 12, 2024

   · 

  4 min read
• Business

  Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

  Precision BioSciences, Inc. today received an upfront cash payment and equity investment from TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications outside of cancer.

  February 12, 2024

   · 

  8 min read